Corcept Therapeutics (CORT) FCF Margin (2012 - 2026)
Corcept Therapeutics (CORT) posted FCF Margin of 12.11% for Q2 2026, up 217.64% sequentially from 10.29% in Q1 2026, and down 1065.0% YoY from 1.25% in Q2 2025.
Corcept Therapeutics (CORT) FCF Margin (2012 - 2026) Analysis & Trends
Corcept Therapeutics has reported FCF Margin for 15 years, with the latest figure at 12.11% in Q2 2026.
- Quarterly FCF Margin fell 1065.0% year-over-year to 12.11% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 12.87% (down 1234.0% YoY) and the FY2025 annual result came in at 18.62%, down 1043.0% from the prior year.
- FCF Margin grew to 12.11% in Q2 2026 per CORT's latest filing, from 10.29% in the prior quarter.
- Over five years, FCF Margin peaked at 42.78% in Q3 2023 and troughed at 10.29% in Q1 2026.
- A 5-year average of 22.97% and a median of 24.73% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2024: FCF Margin slumped 3085 bps in 2022, then surged 2887 bps in 2024.
- Over 5 years, FCF Margin stood at 32.37% in 2022, then slumped by 87 bps to 4.08% in 2023, then jumped by 707 bps to 32.95% in 2024, then tumbled by 42 bps to 19.0% in 2025, then tumbled by 36 bps to 12.11% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 12.11%, 10.29%, and 19.0% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 12.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.11% |
| Mar 31, 2026 | -10.29% |
| Dec 31, 2025 | 19.00% |
| Sep 30, 2025 | 26.24% |
| Jun 30, 2025 | 22.75% |
| Mar 31, 2025 | 2.97% |
| Dec 31, 2024 | 32.95% |
| Sep 30, 2024 | 39.25% |
| Jun 30, 2024 | 24.89% |
| Mar 31, 2024 | 16.18% |
| Dec 31, 2023 | 4.08% |
| Sep 30, 2023 | 42.78% |
| Jun 30, 2023 | 35.84% |
| Mar 31, 2023 | 24.57% |
| Dec 31, 2022 | 32.37% |
| Sep 30, 2022 | 32.73% |
| Jun 30, 2022 | 17.43% |
| Mar 31, 2022 | 37.61% |
| Dec 31, 2021 | 49.95% |
| Sep 30, 2021 | 50.50% |